Haemodynamic efficacy of microaxial left ventricular assist device in cardiogenic shock: a systematic review and meta-analysis

The Impella percutaneous mechanical circulatory support device is designed to augment cardiac output and reduce left ventricular wall stress and aims to improve survival in cases of cardiogenic shock. In this meta-analysis we investigated the haemodynamic effects of the Impella device in a clinical setting. We systematically searched all articles in PubMed/Medline and Embase up to July 2019. The primary outcom

Synthesis and Investigation of a Radioiodinated F3 Peptide Analog as a SPECT Tumor Imaging Radioligand

A radioiodinated derivative of the tumor-homing F3 peptide, (N-(2-{3-[125I]Iodobenzoyl}aminoethyl)maleimide-F3Cys peptide, [125I]IBMF3 was developed for investigation as a SPECT tumor imaging radioligand. For this purpose, we custom synthesized a modified F3 peptide analog (F3Cys) incorporating a C-terminal cysteine residue for site-specific attachment of a radioiodinated maleimide conjugating group. Initial proof-of-concept Fluorescence studies conducted with AlexaFluor 532 C5 maleimide-labeled F3Cys showed distinct membrane and nuclear localization of F3Cys in MDA-MB-435 cells. Additionally, F3Cys conjugated with NIR fluorochrome AlexaFluor 647 C2 maleimide demonstrated high tumor specific uptake in melanoma cancer MDA-MB-435 and lung cancer A549 xenografts in nude mice whereas a similarly labeled control peptide did not show any tumor uptake. These results were also confirmed by ex vivo tissue analysis. No-carrier-added [125I]IBMF3 was synthesized by a radioiododestannylation approach in 73% overall radiochemical yield. In vitro cell uptake studies conducted with [125I]IBMF3 displayed a 5-fold increase in its cell uptake at 4 h when compared to controls. SPECT imaging studies with [125I]IBMF3 in tumor bearing nude mice showed clear visualization of MDA-MB-435 xenografts on systemic administration. These studies demonstrate a potential utility of F3 peptide-based radioligands for tumor imaging with PET or SPECT techniques

Early inhaled budesonide for the prevention of bronchopulmonary dysplasia

BACKGROUND Systemic glucocorticoids reduce the incidence of bronchopulmonary dysplasia among extremely preterm infants, but they may compromise brain development. The effects of inhaled glucocorticoids on outcomes in these infants are unclear. METHODS We randomly assigned 863 infants (gestational age, 23 weeks 0 days to 27 weeks 6 days) to early (within 24 hours after birth) inhaled budesonide or placebo until they no longer required oxygen and positive-pressure support or until they reached a postmenstrual age of 32 weeks 0 days. The primary outcome was death or bronchopulmonary dysplasia, confirmed by means of standardized oxygen-saturation monitoring, at a postmenstrual age of 36 weeks. RESULTS A total of 175 of 437 infants assigned to budesonide for whom adequate data were available (40.0%), as compared with 194 of 419 infants assigned to placebo for whom adequate data were available (46.3%), died or had bronchopulmonary dysplasia (relative risk, stratified according to gestational age, 0.86; 95% confidence interval [CI], 0.75 to 1.00; P = 0.05). The incidence of bronchopulmonary dysplasia was 27.8% in the budesonide group versus 38.0% in the placebo group (relative risk, stratified according to gestational age, 0.74; 95% CI, 0.60 to 0.91; P = 0.004); death occurred in 16.9% and 13.6% of the patients, respectively (relative risk, stratified according to gestational age, 1.24; 95% CI, 0.91 to 1.69; P = 0.17). The proportion of infants who required surgical closure of a patent ductus arteriosus was lower in the budesonide group than in the placebo group (relative risk, stratified according to gestational age, 0.55; 95% CI, 0.36 to 0.83; P = 0.004), as was the proportion of infants who required reintubation (relative risk, stratified according to gestational age, 0.58; 95% CI, 0.35 to 0.96; P = 0.03). Rates of other neonatal illnesses and adverse events were similar in the two groups. CONCLUSIONS Among extremely preterm infants, the incidence of bronchopulmonary dysplasia was lower among those who received early inhaled budesonide than among those who received placebo, but the advantage may have been gained at the expense of increased mortality

Circuit-based interrogation of sleep control.

Sleep is a fundamental biological process observed widely in the animal kingdom, but the neural circuits generating sleep remain poorly understood. Understanding the brain mechanisms controlling sleep requires the identification of key neurons in the control circuits and mapping of their synaptic connections. Technical innovations over the past decade have greatly facilitated dissection of the sleep circuits. This has set the stage for understanding how a variety of environmental and physiological factors influence sleep. The ability to initiate and terminate sleep on command will also help us to elucidate its functions within and beyond the brain

Measurement of the Λc+\Lambda_c^+ lifetime

An absolute measurement of the $\Lambda^{+}_c$ lifetime is reported using $\Lambda_c^+\rightarrow pK^-\pi^+$ decays in events reconstructed from data collected by the Belle II experiment at the SuperKEKB asymmetric-energy electron-positron collider. The total integrated luminosity of the data sample, which was collected at center-of-mass energies at or near the $\Upsilon(4S)$ resonance, is 207.2~\mbox{fb}^{-1}. The result, $\tau(\Lambda^{+}_c) = 203.20 \pm 0.89 \,\mathrm{(stat)} \pm 0.77 \,\mathrm{(syst)}$ fs, is the most precise measurement to date and is consistent with previous determinations.Comment: Accepted for publication in PR

Search for an invisible Z′Z^\prime in a final state with two muons and missing energy at Belle II

The $L_{\mu}-L_{\tau}$ extension of the standard model predicts the existence of a lepton-flavor-universality-violating $Z^{\prime}$ boson that couples only to the heavier lepton families. We search for such a $Z^\prime$ through its invisible decay in the process $e^+ e^- \to \mu^+ \mu^- Z^{\prime}$. We use a sample of electron-positron collisions at a center-of-mass energy of 10.58GeV collected by the Belle II experiment in 2019-2020, corresponding to an integrated luminosity of 79.7fb$^{-1}$. We find no excess over the expected standard-model background. We set 90$\%$-confidence-level upper limits on the cross section for this process as well as on the coupling of the model, which ranges from $3 \times 10^{-3}$ at low $Z^{\prime}$ masses to 1 at $Z^{\prime}$ masses of 8$GeV/c^{2}$

Measurement of CPCP asymmetries in B0→ϕKS0B^0\to \phi K^0_S decays with Belle II

We present a measurement of time-dependent rate asymmetries in $B^0\to \phi K^0_S$ decays to search for non-standard-model physics in $b\to q \overline{q}s$ transitions. The data sample is collected with the Belle II detector at the SuperKEKB asymmetric-energy $e^{+}e^{-}$ collider in 2019-2022 and contains $(387\pm 6)\times 10^6$ bottom-antibottom mesons from $\Upsilon(4S)$ resonance decays. We reconstruct $162\pm17$ signal events and extract the charge-parity ($CP$) violating parameters from a fit to the distribution of the proper-decay-time difference of the two $B$ mesons. The measured direct and mixing-induced $CP$ asymmetries are $A=0.31\pm0.20\pm0.05$ and $S=0.54\pm0.26^{+0.06}_{-0.08}$, respectively, where the first uncertainties are statistical and the second are systematic. The results are compatible with the $CP$ asymmetries observed in $b\to c\overline{c} s$ transitions

Search for Axionlike Particles Produced in e⁺ e⁻ Collisions at Belle II

International audienceWe present a search for the direct production of a light pseudoscalar a decaying into two photons with the Belle II detector at the SuperKEKB collider. We search for the process e+e-→γa, a→γγ in the mass range 0.2

Precise Measurement of the D0^{0} and D+^{+} Lifetimes at Belle II

We report a measurement of the D$^{0}$ and D$^{+}$ lifetimes using D$^{0}$→K$^{-}$π$^{+}$ and D$^{+}$→K$^{-}$π$^{+}$π$^{+}$ decays reconstructed in e$^{+}$e$^{-}$→$\overline{cc}$ data recorded by the Belle II experiment at the SuperKEKB asymmetric-energy e$^{+}$e$^{-}$ collider. The data, collected at center-of-mass energies at or near the Υ(4S) resonance, correspond to an integrated luminosity of 72 fb$^{-1}$. The results, τ(D$^{0}$)=410.5±1.1(stat)±0.8(syst)  fs and τ(D$^{+}$)=1030.4±4.7(stat)±3.1(syst) fs, are the most precise to date and are consistent with previous determinations

Measurement of the τ\tau-lepton mass with the Belle~II experiment

We present a measurement of the $\tau$-lepton mass using a sample of about 175 million $e^+e^- \to \tau^+\tau^-$ events collected with the Belle II detector at the SuperKEKB $e^+e^-$ collider at a center-of-mass energy of $10.579\,\mathrm{Ge\kern -0.1em V}$. This sample corresponds to an integrated luminosity of $190\,\mathrm{fb^{-1}}$. We use the kinematic edge of the $\tau$ pseudomass distribution in the decay ${\tau^-\to\pi^-\pi^+\pi^-\nu_\tau}$ and measure the $\tau$ mass to be $1777.09 \pm 0.08 \pm 0.11 \,\mathrm{Me\kern -0.1em V\!/c^2}$, where the first uncertainty is statistical and the second systematic. This result is the most precise to date